luliconazole
Trade name: luzu
Approved
Nov 14, 2013
Luliconazole (trade names Luzu, Lulicon) is an imidazole antifungal drug. As a 1% topical cream, It is indicated for the treatment of athlete's foot, jock itch, and ringworm caused by dermatophytes such as Trichophyton rubrum, Microsporum gypseum and Epidermophyton floccosum. Luliconazole is an antifungal that belongs to the azole class. Although the exact mechanism of action against dermatophytes is unknown, luliconazole appears to inhibit ergosterol synthesis by inhibiting the enzyme lanosterol demethylase. Inhibition of this enzyme’s activity by azoles results in decreased amounts of ergosterol, a constituent of fungal cell membranes, and a corresponding accumulation of lanosterol. Pharmacokinetic and safety results from phase 1 studies in patients with onychomycosis have demonstrated high concentrations of luliconazole within the nail plates of the great toe and have shown that this agent is well tolerated when administered as a 10% solution. — NCATS
Clinical trial activity
10 trials · 5 clinical orgs · 2 marketing orgs
Earliest trial started Mar 1, 2009 (NCT00869336)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2011
- Nov 14, 2013
Medicis — Earliest FDA Approval
- Nov 14, 2013
Bausch Health Companies — Marketing Organization
- Nov 14, 2013
Medicis — NDA Organization
- Nov 14, 2013
Bausch Health Companies — NDA Secondary Org
Indications
Approved for
Mechanism of action
- Cytochrome P450 51INHIBITOR
ERG11 inhibitor
Approval history
- approvedNov 14, 2013
Chemistry & pharmacology
SMILES
ClC1=CC(Cl)=C(C=C1)[C@@H]2CS\C(S2)=C(\C#N)N3C=CN=C3- Mol. weight
- 354.277 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaLuliconazole ↗
- NCATSRE91AN4S8G ↗
- ChEMBLCHEMBL2105689 ↗
Also known as
- 33525
- 4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene-1-imidazolylacetonitrile
- lulicon
- luliconazole
- luliconazole
- luliconazole
- luliconazole
- luliconazole
- luliconazole
- luliconazole
- luliconazole
- luliconazole
- luliconazole
- luliconazole
- luzu
- luzu
- luzu
- nnd502
- nnd 502
- nnd-502
- nnd-502
- nnd-502
- nnd-502
- pr-2699
- pr-2699
- pr-2699
- product 33525
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05110638 | Phase 1 | Sep 13, 2021 | J&S Studies Inc., Sato Pharmaceutical |
| NCT02767947 | Phase 4 | Feb 8, 2016 | Bausch Health Companies |
| NCT02767271 | Phase 4 | Dec 14, 2015 | Bausch Health Companies |
| NCT01431820 | Phase 2/Phase 3 (Phase 3) | May 1, 2012 | Tinea Pharmaceuticals |
| NCT01396811 | Phase 3 | Jul 1, 2011 | Medicis |
| NCT01396785 | Phase 3 | Jul 1, 2011 | Medicis |
| NCT01349998 | Phase 3 | May 1, 2011 | Tinea Pharmaceuticals |
| NCT01342315 | Phase 3 | May 1, 2011 | Medicis |
| NCT01044381 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2010 | J&S Studies Inc., Tinea Pharmaceuticals |
| NCT00869336 | Phase 2 | Mar 1, 2009 | Tinea Pharmaceuticals |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tinea Pharmaceuticals | For profit | 4 | 4 | 2 | 2009 |
| Medicis | For profit | 3 | 3 | 1 | 2011 |
| Bausch Health Companies | For profit | 2 | 2 | 1 | 2015 |
| J&S Studies Inc. | For profit | 2 | 0 | 2 | 2010 |
| Sato Pharmaceutical | For profit | 1 | 1 | 1 | 2021 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bausch Health Companies | For profit | MKTG | Nov 14, 2013 |
| Bausch Health Companies | For profit | NDA2 | Nov 14, 2013 |
| Medicis | For profit | NDA | Nov 14, 2013 |